CKD-388

CKD-388 is an investigational oral small molecule drug developed by Chong Kun Dang for the treatment of chronic hepatitis B. It is being evaluated as a potential alternative to tenofovir alafenamide (the active ingredient in Vemlidi), with clinical trials designed to assess its safety, pharmacokinetics, and tolerability in healthy subjects. The drug is intended to address hepatitis B infection and may be positioned as a competitor or follow-on product to existing nucleotide analogues used for this indication[2][8]. The specific mechanism of action has not been publicly disclosed, but it is likely related to inhibition of hepatitis B virus replication, similar to other drugs in this class[2].